Emcure Pharmaceuticals , a leading Indian pharmaceutical company, has reported robust financial results for the second quarter, demonstrating significant growth across key metrics.

Financial Highlights

The company's consolidated financial results for Q2 show impressive year-on-year growth:

Emcure's EBITDA margin improved to 19.34%, up from 19.02% in the same quarter last year, indicating enhanced operational efficiency.

Segment Performance

The company witnessed growth across both its domestic and international businesses:

• Domestic sales reached ₹1,031.00 crore, marking a 10.6% increase year-on-year.
• International business sales grew by 15.8% to ₹1,238.00 crore.

Geographic Breakdown

Emcure's international markets showed strong performance:

• Europe: 23% growth, driven by new product launches and Manx ramp-up.
• Canada: 18% growth, continuing its robust performance.
• Emerging Markets (EM): 8.6% growth, with sustained momentum in non-ARV business.

Strategic Developments

Emcure announced a partnership with Novo Nordisk to launch Poviztra®, a biological injectable semaglutide, in India. As the exclusive distributor, Emcure will be responsible for the commercialization and promotion of Poviztra, which is indicated for chronic weight management and cardiovascular risk reduction in overweight or obese individuals.

The company also completed the acquisition of the minority stake in its subsidiary, Zuventus Healthcare Ltd, making it a wholly-owned subsidiary.

Management Commentary

Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals Ltd., commented on the results: "Q2 saw strong performance across all our businesses. We continue to augment our portfolio in all our focus markets through in-licensing and in-house developments. The Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry enabling us to shape the market. We remained focused on delivering strong growth along with margin improvement in all our key businesses."

The company's focus on innovation, strategic partnerships, and expansion in both domestic and international markets appears to be driving its growth trajectory. With a diverse product portfolio and a strong presence in over 70 countries, Emcure Pharmaceuticals is well-positioned to capitalize on opportunities in the global pharmaceutical market.

Investors and stakeholders can access more details about the company's performance through an earnings call scheduled for November 11 at 3:00 p.m. IST.

Emcure Pharmaceuticals has entered into a strategic partnership with Novo Nordisk India to distribute Povitra®, a second brand of the weight loss drug Wegovy®, in India. This collaboration marks a significant step in expanding access to innovative weight management solutions in the country.

Partnership Details

• Exclusive Distribution Rights: Emcure Pharmaceuticals becomes the sole distributor for Semaglutide Injection 2.4 mg in India.
• Product Name: Povitra® (semaglutide injection 2.4 mg)
• Indication: Chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity.

Significance of the Partnership

This collaboration is part of Novo Nordisk's efforts to broaden access to its innovative semaglutide molecule, making it available to a greater number of people living with overweight and obesity in India. The partnership leverages Emcure's robust marketing and distribution capabilities to improve access to obesity treatment across the country.

Key Points

• Emcure Pharmaceuticals becomes the first Indian company with exclusive rights to distribute and commercialize Povitra®.
• The partnership aims to strengthen distribution and marketing, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India.
• Wegovy® (semaglutide injection 2.4 mg) was initially launched in India in June 2025.

Clinical Efficacy

According to clinical trials:

• 1 in 3 participants on Wegovy® experienced weight loss of over 20%.
• Semaglutide has been on the market for nearly a decade with 38 million patient years of exposure.

Market Context

India faces a significant obesity challenge:

This partnership between Emcure Pharmaceuticals and Novo Nordisk India represents a strategic move to address the growing need for effective weight management solutions in the Indian market. By combining Novo Nordisk's innovation in GLP-1 therapies with Emcure's established presence in the Indian pharmaceutical landscape, the collaboration aims to make a significant impact on obesity treatment accessibility in India.

As the obesity epidemic continues to grow, partnerships like this play a crucial role in bringing advanced therapeutic options to patients who need them most, potentially improving health outcomes for millions of individuals across the country.